Delivery Order SPE2DB20D3103-SPE2DB24FN0C5

Award Date 3/13/24
Potential Completion Date 3/14/24
Potential Value $3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,880.32 firm fixed-price contract is for the delivery of the pharmaceutical product XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML. The contract has an ultimate completion date of November 20, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,919.54 firm fixed-price delivery order is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a medical product. The contract has an ultimate completion date of August 25, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML. The delivery order valued at $1,559.66 has a firm fixed price and an ultimate completion date of October 10, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,737.18 firm fixed-price delivery order is for the medical product XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML. The contract has an ultimate completion date of December 9, 2024. This award is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,575.18, is a delivery order for the medication XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML. The contract has a Firm Fixed Price pricing type and an ultimate completion date of March 5, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The $1,339.17 firm-fixed-price delivery order is for the supply of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a specialty medication. The contract has an ultimate completion date of September 6, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December...
This federal contract award is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, from the Defense Logistics Agency (DLA). The $1,050.12 delivery order contract is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a medical product. The contract has a firm fixed price and is not designated with any set-aside requirements, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,084.37 firm fixed price delivery order is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a specialty pharmaceutical product. The contract has an ultimate completion date of November 29, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,162.48 firm fixed-price delivery order is for the supply of XYOSTED 50 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of August 18, 2022. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This federal contract award, valued at $1,655.34, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the medical product "XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML" with a completion date of November 6, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB24FN0C5
    Delivery Order

This federal contract award, valued at $3,005.86, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a specialty pharmaceutical product, with a completion date of March 14, 2024.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries through a streamlined, comprehensive contracting mechanism.

Generated 2/27/25, 12:43 PM